Prefilled Syringes Market (7th Edition), Industry Trends and Global Forecasts, till 2035: Distribution by Purpose of Syringe (Specialty Prefilled Syringes, Therapeutic Prefilled Syringes and Cosmetic Prefilled Syringes), Therapeutic Area (Therapeutic Syringes - Blood Disorders, Infectious Diseases, Autoimmune Disorders, Oncological Disorders, Cardiovascular Disorders, Respiratory Disorders, Neurological Disorders, Metabolic Disorders, Ophthalmic Disorders, Orthopedic Disorders and Others), Type of Molecule (Therapeutic Syringes - Proteins, Antibodies, Peptides, Small Molecules, Vaccines and Cell Therapies), Type of Barrel Material (Glass Syringes and Plastic Syringes), Number of Barrel Chamber (Single Chamber Syringes and Dual Chamber Syringes), Type of Needle System (Staked Needle Syringes and Luer Syringes), Usability of Syringe (Disposable Syringes and Reusable Syringes), Type of Syringe (Conventional Syringes and Safety Syringes), Type of Packaging (Bulk Syringes and Nested Syringes) and Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America)
![](/report_cover/10031/prefilled-syringes-market-7th-edition-industry-trends-n-global-forecasts-till-2035-distribution-by-purpose-of-syringe-specialty-prefilled-syringes_en.gif)
Prefilled Syringes Market (7th Edition), Industry Trends and Global Forecasts, till 2035: Distribution by Purpose of Syringe (Specialty Prefilled Syringes, Therapeutic Prefilled Syringes and Cosmetic Prefilled Syringes), Therapeutic Area (Therapeutic Syringes - Blood Disorders, Infectious Diseases, Autoimmune Disorders, Oncological Disorders, Cardiovascular Disorders, Respiratory Disorders, Neurological Disorders, Metabolic Disorders, Ophthalmic Disorders, Orthopedic Disorders and Others), Type of Molecule (Therapeutic Syringes - Proteins, Antibodies, Peptides, Small Molecules, Vaccines and Cell Therapies), Type of Barrel Material (Glass Syringes and Plastic Syringes), Number of Barrel Chamber (Single Chamber Syringes and Dual Chamber Syringes), Type of Needle System (Staked Needle Syringes and Luer Syringes), Usability of Syringe (Disposable Syringes and Reusable Syringes), Type of Syringe (Conventional Syringes and Safety Syringes), Type of Packaging (Bulk Syringes and Nested Syringes) and Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America)
Report Link: https://www.rootsanalysis.com/reports/prefilled-syringes-market/284.html
The prefilled syringes market is expected to reach USD 3 billion by 2024 anticipated to grow at a CAGR of 4.6% during the forecast period 2024-2035.
The prevalence of chronic disorders such as autoimmune conditions (e.g., rheumatoid arthritis), cardiovascular diseases, diabetes, and oncological disorders has surged globally in recent years. In the United States, nearly 133 million individuals were estimated to be affected by one or more chronic disorders in 2022, with this number anticipated to reach 170 million by 2030. According to a recent study by the US Centers for Disease Control (CDC), the annual economic burden associated with chronic disorders in the US stands at USD 4.1 trillion. A significant portion of these costs arise from the frequent requirement for medication, leading to regular hospital visits. Moreover, patient hesitance towards receiving injections in clinical settings due to privacy concerns or discomfort presents an additional challenge, impacting patient adherence to treatment regimens.
To mitigate these challenges, various self-administration devices like autoinjectors, prefilled syringes, and pen injectors have been developed. Prefilled syringes, in particular, have gained prominence, especially in emergency situations such as anaphylactic shock and rheumatoid arthritis treatment. These syringes come pre-loaded with precise doses of parenteral medication, eliminating the need for manual filling. They offer benefits such as convenience, dose accuracy, reduced risk of contamination, and minimal drug wastage. By reducing the frequency of patient visits to healthcare providers, prefilled syringes contribute to lowering global healthcare expenditures. Currently, various types of prefilled syringes are available, including dual-chamber prefilled syringes, flush syringes, and safety syringes equipped with mechanisms to prevent needlestick injuries. With the growing adoption of self-administering parenteral devices, ongoing technological advancements, and increasing preference for home healthcare services, the global prefilled syringes market is poised for significant growth in the foreseeable future.
Report Coverage
Report Link: https://www.rootsanalysis.com/reports/prefilled-syringes-market/284.html
The prefilled syringes market is expected to reach USD 3 billion by 2024 anticipated to grow at a CAGR of 4.6% during the forecast period 2024-2035.
The prevalence of chronic disorders such as autoimmune conditions (e.g., rheumatoid arthritis), cardiovascular diseases, diabetes, and oncological disorders has surged globally in recent years. In the United States, nearly 133 million individuals were estimated to be affected by one or more chronic disorders in 2022, with this number anticipated to reach 170 million by 2030. According to a recent study by the US Centers for Disease Control (CDC), the annual economic burden associated with chronic disorders in the US stands at USD 4.1 trillion. A significant portion of these costs arise from the frequent requirement for medication, leading to regular hospital visits. Moreover, patient hesitance towards receiving injections in clinical settings due to privacy concerns or discomfort presents an additional challenge, impacting patient adherence to treatment regimens.
To mitigate these challenges, various self-administration devices like autoinjectors, prefilled syringes, and pen injectors have been developed. Prefilled syringes, in particular, have gained prominence, especially in emergency situations such as anaphylactic shock and rheumatoid arthritis treatment. These syringes come pre-loaded with precise doses of parenteral medication, eliminating the need for manual filling. They offer benefits such as convenience, dose accuracy, reduced risk of contamination, and minimal drug wastage. By reducing the frequency of patient visits to healthcare providers, prefilled syringes contribute to lowering global healthcare expenditures. Currently, various types of prefilled syringes are available, including dual-chamber prefilled syringes, flush syringes, and safety syringes equipped with mechanisms to prevent needlestick injuries. With the growing adoption of self-administering parenteral devices, ongoing technological advancements, and increasing preference for home healthcare services, the global prefilled syringes market is poised for significant growth in the foreseeable future.
Report Coverage
- The report comprehensively examines the prefilled syringe market based on purpose of syringe, therapeutic area, type of molecule, type of barrel material, number of barrel chamber, type of needle system, usability of syringe, type of syringe, type of packaging and key geographical regions.
- It thoroughly analyzes market influences such as drivers, restraints, opportunities, and challenges, while evaluating competitive landscapes for top players. Forecasts are provided for segment revenues across major regions.
- This chapter provides an extensive overview of prefilled syringes, covering their components, historical evolution, and associated benefits. It also examines various types of prefilled syringes categorized by factors such as barrel fabrication material, needle system, and packaging method. The manufacturing process for prefilled syringes is detailed, along with future growth prospects for the industry.
- A comprehensive assessment of the current prefilled syringes market landscape is conducted, considering parameters such as barrel fabrication material, needle system type, and syringe volume. Additionally, the chapter offers an in-depth analysis of prefilled syringe manufacturers, including establishment details, company size, headquarters location, manufacturing facility location, and identification of key players based on production volume.
- Detailed evaluation of prefilled syringe manufacturers' competitiveness, considering factors such as product development stage, barrel chamber count, syringe volume availability, and types of needle systems offered.
- Elaborate profiles of notable prefilled syringe manufacturers located across North America, Europe, and the Asia Pacific region are presented, along with profiles of other prominent players in the industry. Each profile includes company overview details such as establishment year, headquarters location, employee count, and leadership team information. Financial data, if available, is also provided alongside details of the manufacturer's prefilled syringe portfolio, recent advancements, and future outlook.
- The chapter addresses concerns regarding needlestick injuries and outlines safety measures implemented in prefilled syringes, including regional and global legislation efforts. It highlights companies involved in developing and manufacturing safety solutions for prefilled syringes.
- A comprehensive summary of regulatory guidelines set by major regulatory bodies for prefilled syringe approval across different countries and regions.
- An in-depth analysis of combination products available or under evaluation in prefilled syringe form, focusing on injectable drugs and vaccines. This analysis includes approved drugs categorized by drug molecule type, approval year, administration route, and therapeutic area. Additionally, it covers products in clinical stages, considering parameters such as drug molecule type, development phase, administration route, and therapeutic focus, along with insights into the involved drug developers.
- A thorough examination of prevalent therapeutic indications commonly targeted in medical treatment, with detailed information on approved or marketed injectable drug products used across various therapeutic areas, along with insights into biosimilar availability for these drugs.
- A comprehensive overview of marketed drugs or therapies expected to be accessible in prefilled syringe format soon, based on parameters such as historical sales data, drug molecule type, therapeutic area, administration route, and existing dosage forms.
- An assessment of prefilled syringe combination product-related initiatives by major pharmaceutical companies, considering factors such as revenue generation in 2022, number of combination products, target therapeutic areas, and drug molecule types.
- An analysis of partnerships established in the prefilled syringe sector, covering parameters such as initiative year, type, geographical distribution, and key players involved.
- An examination of patents related to prefilled syringes filed or granted since 2019, considering aspects such as patent type, publication year, applicant type, geographical location, CPC symbols, and leading players in terms of patent filings. Additionally, the chapter includes patent benchmarking and valuation analysis focusing on patents with high citation counts, along with identification of key opinion leaders in the prefilled syringe domain based on roles, affiliations, indications, and locations.
- Detailed information on specialty syringes including prefilled flush syringes, diluent systems, and syringes with contrast agents, along with available products in the market and their respective benefits.
- Recent technological advancements in prefilled syringe design and manufacturing are discussed, focusing on innovations enabling lyophilized drug marketing in dual-chambered syringes, as well as advancements in lubrication and sterilization technologies.
- An analysis of factors expected to drive growth in the prefilled syringes market, including the rise in chronic diseases, preference for self-medication, evolving patient preferences, adoption of biologics and biosimilars, pharmaceutical strategies, needlestick injury prevention initiatives, and potential applications of prefilled syringes.
- Industry trends, opportunities, and challenges are discussed under a SWOT analysis, highlighting their potential impact on the prefilled syringes market evolution, accompanied by a Harvey ball analysis illustrating the relative significance of each SWOT parameter on industry dynamics.
- Becton Dickinson and Company
- Credence MedSystems
- Gerresheimer
- J.O.Pharma
- Medefil
- MedXL
- Mitsubishi Gas Chemical
- Nipro PharmaPackaging
- Novartis
- Pfizer
- SCHOTT
- Shandong Pharmaceutical Glass
- Shandong Weigao
- Shin Yan Sheno Precision Industrial
- Stevanato
- Taisei Kako
- Vetter Pharma
- West Pharmaceutical
1. PREFACE
1.1. Prefilled Syringes Market
1.2. Market Share Insights
1.2.1 Market Segmentation Overview
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. History of Prefilled Syringes
5.3. Benefits of Prefilled Syringes Over Traditional Injectable Devices
5.3.1. Benefits of Prefilled Syringes for Healthcare Professionals and End Users
5.3.2. Benefits of Prefilled Syringes for Manufacturers
5.3.3. Transition from Existing Dosing Forms to Prefilled Syringes
5.4. Prefilled Syringe Components
5.5. Classification of Prefilled Syringes
5.5.1. Classification based on Barrel Fabrication Material
5.5.1.1. Glass Barrel Prefilled Syringes
5.5.1.1.1. Limitations of Glass Barrel Prefilled Syringes
5.5.1.1.2. Addressing the Limitations of Glass Barrel Prefilled Syringes
5.5.1.2. Plastic Barrel Prefilled Syringes
5.5.1.2.1. Limitations of Plastic Barrel Prefilled Syringes
5.5.1.2.2. Addressing the Limitations of Plastic Barrel Prefilled Syringes
5.5.1.2.3. Factors Likely to Drive the Use of Plastic Prefilled Syringes
5.5.2. Classification based on Number of Chambers in the Barrel
5.5.3. Classification based on Type of Needle
5.5.4. Classification based on Type of Packaging
5.6. Critical Attributes of Prefilled Syringe Design
5.7. Key Manufacturing Steps for Prefilled Syringes
5.7.1. Production of Barrels
5.7.1.1. Glass Barrels
5.7.1.2. Plastic Barrels
5.7.2. Production of Syringes
5.7.3. Barrel Siliconization
5.7.4. Syringe Sterilization
5.7.5. Validation of Sterilization
5.7.6. Syringe Filling
5.7.7. Syringe Testing
5.8. Future Perspectives
6. PREFILLED SYRINGES: MARKET OVERVIEW
6.1. Chapter Overview
6.2. Prefilled Syringes: Overall Market Landscape
6.2.1. Analysis by Type of Barrel Fabrication Material
6.2.2. Analysis by Number of Barrel Chambers
6.2.3. Analysis by Type of Needle System
6.2.4. Analysis by Volume of Syringe
6.3. Prefilled Syringes Manufacturers: Overall Market Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Analysis by Company Size and Location of Headquarters
6.3.5. Analysis by Location of Manufacturing Facilities
6.3.6. Most Active Players: Analysis by Number of Prefilled Syringes
7. PRODUCT COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Product Competitiveness Analysis: Prefilled Syringes
7.4.1. Glass Barrel Prefilled Syringes
7.4.2. Plastic Barrel Prefilled Syringes
8. COMPANY PROFILES: PREFILLED SYRINGE MANUFACTURERS IN NORTH AMERICA
8.1. Chapter Overview
8.2. Detailed Company Profiles of Leading Prefilled Syringe Manufacturers
8.3.1 Becton, Dickinson and Company
8.3.1.1. Company Overview
8.3.1.2. Financial Information
8.3.1.3. Becton, Dickinson and Company Prefilled Syringes Portfolio
8.3.1.4. Recent Developments and Future Outlook
8.3.2. Medefil
8.3.2.1. Company Overview
8.3.2.2. Medefil Prefilled Syringes Portfolio
8.3.2.3. Recent Developments and Future Outlook
8.3.3. West Pharmaceutical
8.3.3.1. Company Overview
8.3.3.2. Financial Information
8.3.3.2. West Pharmaceutical Prefilled Syringes Portfolio
8.3.3.3. Recent Developments and Future Outlook
8.4. Short Profiles of Other Prominent Prefilled Syringe Manufacturers
8.4.1. Medline
8.4.1.1. Company Overview
8.4.1.2. Prefilled Syringes Portfolio
8.4.2. MedXL
8.4.2.1. Company Overview
8.4.2.2. Prefilled Syringes Portfolio
8.4.3 Pfizer
8.4.3.1. Company Overview
8.4.3.2. Prefilled Syringes Portfolio
9. COMPANY PROFILES: PREFILLED SYRINGE MANUFACTURERS IN EUROPE
9.1. Chapter Overview
9.2. Detailed Company Profiles of Leading Prefilled Syringe Manufacturers
9.3.1. Gerresheimer
9.3.1.1. Company Overview
9.3.1.2. Financial Information
9.3.1.3. Gerresheimer Prefilled Syringes Portfolio
9.3.1.4. Recent Developments and Future Outlook
9.3.2 SCHOTT
9.3.2.1. Company Overview
9.3.2.2. Financial Information
9.3.2.3. Schott Prefilled Syringes Portfolio
9.3.2.4. Recent Developments and Future Outlook
9.3.3. Stevanato
9.3.3.1. Company Overview
9.3.2.2. Financial Information
9.3.3.3. Stevanato Prefilled Syringes Portfolio
9.3.3.4. Recent Developments and Future Outlook
9.4. Short Profiles of Other Prominent Prefilled Syringe Manufacturers
9.4.1 B. Braun
9.4.1.1. Company Overview
9.4.1.2. Prefilled Syringes Portfolio
9.4.2. Nipro Europe
9.4.2.1. Company Overview
9.4.2.2. Prefilled Syringes Portfolio
9.4.3. Vetter Pharma
9.4.3.1. Company Overview
9.4.3.2. Prefilled Syringes Portfolio
10. COMPANY PROFILES: PREFILLED SYRINGE MANUFACTURERS IN ASIA-PACIFIC
10.1. Chapter Overview
10.2. Detailed Company Profiles of Leading Prefilled Syringe Manufacturers
10.2.1 Shandong Zibo Minkang Pharmaceutical Packing
10.2.1.1. Company Overview
10.2.1.2. Shandong Zibo Minkang Pharmaceutical Packing Prefilled Syringes Portfolio
10.2.1.3. Recent Developments and Future Outlook
10.2.2. Shin Yan Sheno Precision Industrial
10.2.2.1. Company Overview
10.2.2.2. Taisei Kako Prefilled Syringes Portfolio
10.2.2.3. Recent Developments and Future Outlook
10.2.3. Taisei Kako
10.2.3.1. Company Overview
10.2.3.2. Taisei Kako Prefilled Syringes Portfolio
10.2.3.3. Recent Developments and Future Outlook
10.3. Short Profiles of Other Prominent Prefilled Syringe Manufacturers
10.3.1 J.O.Pharma
10.3.1.1. Company Overview
10.3.1.2. Prefilled Syringes Portfolio
10.3.2. Shandong Pharmaceutical Glass
10.3.2.1. Company Overview
10.3.2.2. Prefilled Syringes Portfolio
10.3.3. Shandong Weigao Group Medical Polymer
10.3.3.1. Company Overview
10.3.3.2. Prefilled Syringes Portfolio
11. NEEDLESTICK INJURIES
11.1. Chapter Overview
11.2. Incidence and Associated Financial Burden
11.3. Government Legislations for Prevention of Needlestick Injuries
11.4. Safety Mechanisms used in Modern Prefilled Syringes
11.4.1. Safety Systems: Add-On Safety Device Manufacturers
11.4.1.1. Becton Dickinson and Company
11.4.1.2. Nemera
11.4.1.3. Nipro PharmaPackagin
11.4.1.4. Terumo
11.4.1.5. West Pharmaceutical
11.4.2. Safety Systems: Integrated Safety Device Manufacturers
11.4.2.1. Gerresheimer
11.4.2.2. Injecto
11.4.2.3. MedicalChain International
11.4.2.4. Stevanato
11.4.2.5. Owen Mumford
11.4.2.6. SHL Group
11.4.2.7. Taisei Kako
12. REGULATORY LANDSCAPE FOR PREFILLED SYRINGES
12.1. Chapter Overview
12.2. Regulatory Approval of Combination Products in North America
12.2.1. Regulatory Approval of Combination Products in the US
12.2.1.1. Overview
12.2.1.2. Historical Background
12.1.1.3. Role of Regulatory Bodies in Product Approval
12.1.1.4. Regulatory Approval of Prefilled Syringes
12.1.1.4.1. Reimbursement Landscape in the US
12.1.1.4.2. Payer Mix
12.1.1.4.3.. Reimbursement Process in the US
12.2.2. Regulatory Approval of Combination Products in Canada
12.2.2.1. Overview
12.2.2.2. Role of Regulatory Bodies in Product Approval
12.2.2.3. Regulatory Approval for Prefilled Syringes
12.2.2.3.1. Reimbursement Landscape in Canada
12.2.2.3.2. Payer Mix
12.2.2.3.3. Reimbursement Process in Canada
12.3. Regulatory Approval of Combination Products in Europe
12.3.1. Overview
12.3.2. Role of Regulatory Bodies in Product Approval
12.3.3. Regulatory Approval of Prefilled Syringes
12.3.4. Regulatory Approval of Combination Products in the UK
12.3.4.1. Reimbursement Landscape in the UK
12.3.4.2. Payer Mix
12.3.4.3. Reimbursement Process in the UK
12.3.5. Regulatory Approval of Combination Products in France
12.3.5.1. Reimbursement Landscape in France
12.3.5.2. Payer Mix
12.3.5.3. Reimbursement Process in France
12.3.6. Regulatory Approval of Combination Products in Spain
12.3.6.1. Reimbursement Landscape in Spain
12.3.6.2. Payer Mix
12.3.6.3. Reimbursement Process in Spain
12.3.7. Regulatory Approval of Combination Products in Spain
12.3.7.1. Reimbursement Landscape in Germany
12.3.7.2. Payer Mix
12.3.7.3. Reimbursement Process in Germany
12.3.8. Regulatory Approval of Combination Products in Italy
12.3.8.1. Reimbursement Landscape in Italy
12.3.8.2. Payer Mix
12.3.8.3. Reimbursement Process in Italy
12.4. Regulatory Approval of Combination Products in Asia-Pacific
12.4.1. Regulatory Approval of Combination Products in Japan
12.4.1.1 Overview
12.4.1.2 Role of Regulatory Bodies in Product Approval
12.4.1.3. Regulatory Approval of Prefilled Syringes
12.4.1.3.1. Reimbursement Landscape in Japan
12.4.1.3.2. Payer Mix
12.4.1.3.3. Reimbursement Process in Japan
12.4.2. Regulatory Approval of Combination Products in China
12.4.2.1. Overview
12.4.2.2. Role of Regulatory Bodies in Product Approval
12.4.2.3. Regulatory Approval for Prefilled syringes
12.4.2.3.1. Reimbursement Landscape in China
12.4.2.3.2. Payer Mix
12.4.2.3.3. Reimbursement Process in China
12.4.3. Regulatory Approval of Combination Products in India
12.4.3.1. Overview
12.4.3.2. Role of Regulatory Bodies in Product Approval
12.4.3.3. Regulatory Approval of Prefilled Syringes
12.4.3.3.1. Reimbursement Landscape in India
12.4.3.3.2. Payer Mix
12.4.4. Regulatory Approval of Combination Products in South Korea
12.4.4.1. Overview
12.4.4.2. Role of Regulatory Bodies in Product Approval
12.4.4.3. Regulatory Approval of Prefilled Syringes
12.4.4.3.1. Reimbursement Landscape in South Korea
12.4.4.3.2. Payer Mix
12.4.4.3.3. Reimbursement Process in South Korea
12.4.5. Regulatory Approval of Combination Products in Saudi Arabia
12.4.5.1. Overview
12.4.5.2. Role of Regulatory Bodies in Product Approval
12.4.5.3. Regulatory Approval of Prefilled syringes
12.4.5.3.1. Reimbursement Landscape in Saudi Arabia
12.4.5.3.2. Payer Mix
12.4.5.3.3. Reimbursement Process in Saudi Arabia
12.4.6. Regulatory Approval of Combination Products in United Arab Emirates
12.4.6.1. Overview
12.4.6.2. Role of Regulatory Bodies in Product Approval
12.4.6.3. Regulatory Approval of Prefilled syringes
12.4.6.3.1. Reimbursement Landscape in United Arab Emirates
12.4.6.3.2. Payer Mix
12.4.6.3.3. Reimbursement Process in United Arab Emirates
12.5. Regulatory Approval of Combination Products in Rest of the World
12.5.1. Regulatory Approval of Combination Products in Brazil
12.5.1.1 Overview
12.5.1.2 Role of Regulatory Bodies in Product Approval
12.5.1.3. Regulatory Approval of Prefilled Syringes
12.5.1.3.1. Reimbursement Landscape in Brazil
12.5.1.3.2. Payer Mix
12.5.1.3.3. Reimbursement Process in Brazil
12.5.2. Regulatory Approval of Combination Products in Australia
12.5.2.1 Overview
12.5.2.2 Role of Regulatory Bodies in Product Approval
12.5.2.3. Regulatory Approval of Prefilled Syringes
12.5.2.3.1. Reimbursement Landscape in Australia
12.5.2.3.2. Payer Mix
12.5.2.3.3. Reimbursement Process in Australia
13. PREFILLED SYRINGE COMBINATION PRODUCTS
13.1. Chapter Overview
13.2. Prefilled Syringe Combination Products: Approved Drugs
13.2.1. Analysis by Type of Drug Molecule
13.2.2. Analysis by Product Approval
13.2.3. Analysis by Route of Administration
13.2.4. Analysis by Target Therapeutic Area
13.2.5. Analysis by Region of Product Analysis
13.2.6. Analysis by Other Approved Primary Packaging Systems
13.3. Prefilled Syringe Combination Products: Clinical Stage Drugs
13.3.1. Analysis by Type of Drug Molecule
13.3.2. Analysis by Phase of Development
13.3.3. Analysis by Route of Administration
13.3.4. Analysis by Target Therapeutic Area
13.4. Prefilled Syringe Combination Products: Developers Landscape
13.4.1. Analysis by Year of Establishment
13.4.2. Analysis by Company Size
13.4.3. Analysis by Location of Headquarters
13.5. Leading Drugs in Prefilled Syringe Format
13.6. Other Drugs Available in Prefilled Syringe Format
13.7. Most Popular Drug Available in Prefilled Syringe Format: Humira (adalimumab), AbbVie / Eisai
13.7.1. Target Indications and Available Dosage Forms
13.7.2. Shift from Vials to Prefilled Syringes
13.7.3. Humira Annual Sales, FY 2010-FY 2022
14. KEY THERAPEUTIC AREAS
14.1. Chapter Overview
14.2. Autoimmune Disorders
14.2.1. Approved Drugs
14.2.2. Key Developments
14.2.3. Upcoming / Commercialized Biosimilars for Autoimmune Drugs
14.3. Infectious Diseases
14.3.1. Approved Drugs
14.3.2. Key Developments
14.4. Neurological Disorders
14.4.1. Approved Drugs
14.4.2. Key Developments
15. PREFILLED SYRINGES: LIKELY DRUG CANDIDATES ANALYSIS
15.1. Chapter Overview
15.2. Likely Drug Candidates
15.2.1. Assumption and Key Parameters
15.2.2. Methodology
15.2.3. Most Likely Candidates for Delivery via Prefilled Syringes
15.2.4. Likely Candidates for Delivery via Prefilled Syringes
15.2.5. Less Likely Candidates for Delivery Via Prefilled Syringe
16. COMBINATION PRODUCTS: BIG PHARMA ACTIVITY
16.1. Chapter Overview
16.2. Methodology
16.3. Combination Products: Big Pharma Activity
16.3.1. Analysis by Target Therapeutic Area
16.3.1.1. Autoimmune Disorders
16.3.1.2. Infectious Diseases
16.3.1.3. Neurological Disorders
16.3.1.4. Blood Disorders
16.3.1.5. Oncological Disorders
16.3.2. Analysis by Type of Molecule
16.3.2.1. Antibodies
16.3.2.2. Vaccines
16.3.2.3. Proteins
16.3.2.4. Peptides
16.3.2.5. Small Molecules
16.3.2.6. Other Biologics
17. RECENT DEVELOPMENTS
17.1. Chapter Overview
17.2. Prefilled Syringes: Recent Developments
17.3. Analysis by Year of Initiative
17.4. Analysis by Type of Initiative
17.5. Analysis by Year and Type of Initiative
17.5.1. Analysis by Location of Expansion
17.5.2. Analysis by Type of Expansion
17.5.3 Analysis by Type of Partnership
17.6. Analysis by Geography
17.7. Most Active Players: Distribution by Number of Recent Initiatives
17.8. Analysis of Player by Type of Initiatives
18. PATENT ANALYSIS
18.1. Chapter Overview
18.2. Scope and Methodology
18.3. Prefilled Syringes: Patent Analysis
18.3.1. Analysis by Patent Publication Year
18.3.2. Analysis by Type of Patent and Publication Year
18.3.3. Analysis by Patent Application Year
18.3.4. Analysis by Patent Jurisdiction
18.3.5. Analysis by CPC Symbols
18.3.6. Analysis by Type of Applicant
18.3.7. Leading Players: Analysis by Number of Patents
18.3.8. Leading Individual Assignees: Analysis by Number of Patents
18.4. Prefilled Syringes: Patent Benchmarking Analysis
18.4.1. Analysis by Patent Characteristics
18.5. Prefilled Syringes: Patent Valuation Analysis
18.6. Leading Patents by Number of Citations
19. KOL ANALYSIS
19.1. Chapter Overview
19.2. Assumption and Key Parameters
19.3. Methodology
19.4. Prefilled Syringes: Key Opinion Leaders
19.4.1. Analysis by Role of KOL
19.4.2. Analysis by Type of Sponsor Organization
19.4.3. Analysis by Affiliated Organization
19.4.4. Analysis by Target Disease Indication
19.4.5. Analysis by Geographical Location
19.4.6. Most Prominent KOLs: Analysis by Activeness, Expertise and Strength of KOL
19.4.7. Most Prominent KOLs: Analysis by RA score
20. SPECIALTY PREFILLED SYRINGES
20.1. Chapter Overview
20.2. Prefilled Flush Syringes
20.2.1. Overview
20.2.2. Advantages of Prefilled Flush Syringes
20.2.3. Prefilled Flush Syringes Available in the Market
20.3. Prefilled Diluent Syringes
20.3.1. Overview
20.3.2. Advantages of Prefilled Diluent Syringes
20.3.3. Lyophilized Drugs Available in Prefilled Diluent Syringes
20.4. Contrast Agent Prefilled Syringes
20.4.1. Overview
20.4.2. Advantages of Using Prefilled Syringes for Contrast Agents
20.4.3. Contrast Agents Available in Prefilled Syringes
21. TECHNOLOGICAL ADVANCES RELATED TO PREFILLED SYRINGES
21.1. Chapter Overview
21.2. Prefilled Syringes for Lyophilized Drugs
21.2.1. Prefilled Diluent Syringes
21.2.2. Prefilled Dual-Chamber Syringes
21.3. Multilayer Plastic Prefilled Syringes with Oxygen Barrier
21.4. Prefilled Syringes with Low Risk of Particle Formation
21.5. Advanced Lubrication Technology for Prefilled Syringes
21.6. Advances in Terminal Sterilization of Prefilled Syringes
21.7. Prefilled Syringe Usage Aids for Patients and Healthcare Providers
21.8. Additional Advancements
22. KEY GROWTH DRIVERS
22.1. Chapter Overview
22.2. Rising Incidence of Chronic Diseases
22.3. Growing Preference for Self-Injection
22.4. Evolving Patient Demographics
22.5. Growth of Biologics and Biosimilars Market
22.6. Changing Pharmaceutical Practices
22.7. Increasing Focus on Prevention of Needlestick Injuries
22.8. Prefilled Syringes in Autoinjectors and Pen Injectors
23. SWOT ANALYSIS
23.1. Chapter Overview
23.2. Strengths
23.2.1. Ease of Use
23.2.2. Ability to Reduce / Eliminate Medication Errors
23.2.3. Reducing the Risk of Accidental Transmission of Blood-Borne Pathogens
23.2.4. Economic Advantages
23.2.5. Drug Life Cycle Management
23.3. Weaknesses
23.3.1. Manufacturing Complexities
23.3.2. High Packaging and Transportation Costs
23.3.3. Product Stability and Quality Related Issues
23.3.4. Challenges Associated with Drug Filing
23.4. Opportunities
23.4.1. Rich and Growing Pipeline of Biologics and Biosimilars
23.4.2. Growing Preference for Self-Injecting
23.4.3. Application in Advanced Drug Delivery Devices
23.4.4. Innovation in Design and Technical Advancement
23.4.5. Rising Popularity across the Globe
23.4.6. Widespread Use in Vaccination Programs
23.5. Threats
23.5.1. Material Compatibility Issues
23.5.2. Availability of Alternative Drug Delivery Devices
23.5.3. Concern Related to Numerous Product Recalls In Past
23.6. Concluding Remarks
24. GLOBAL PREFILLED SYRINGES MARKET
24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Global Prefilled Syringes Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.1. Scenario Analysis
24.4. Key Market Segmentations
25. PREFILLED SYRINGES MARKET, BY PURPOSE OF SYRINGE
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Prefilled Syringes Market: Distribution by Purpose of Syringe, 2018, 2023 and 2035
25.3.1. Specialty Prefilled Syringe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.2. Therapeutic Prefilled Syringe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.3. Cosmetic Prefilled Syringe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.4. Data Triangulation and Validation
26. PREFILLED SYRINGES MARKET, BY TYPE OF MOLECULE
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Prefilled Syringes Market: Distribution by Type of Molecule, 2018, 2023 and 2035
26.3.1. Prefilled Syringes Market for Proteins: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.2. Prefilled Syringes Market for Antibodies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.3. Prefilled Syringes Market for Peptides: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.4. Prefilled Syringes Market for Small Molecules: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.5. Prefilled Syringes Market for Vaccines: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.6. Prefilled Syringes Market for Cell Therapies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.4. Data Triangulation and Validation
27. PREFILLED SYRINGES MARKET, BY THERAPEUTIC AREA
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Prefilled Syringes Market: Distribution by Therapeutic Area, 2018, 2023 and 2035
27.3.1. Prefilled Syringes Market for Blood Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.2. Prefilled Syringes Market for Infectious Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.3. Prefilled Syringes Market for Autoimmune Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.4. Prefilled Syringes Market for Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.5. Prefilled Syringes Market for Cardiovascular Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.6. Prefilled Syringes Market for Respiratory Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.7. Prefilled Syringes Market for Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.8. Prefilled Syringes Market for Metabolic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.9. Prefilled Syringes Market for Ophthalmic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.10. Prefilled Syringes Market for Orthopedic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.11 Prefilled Syringes Market for Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.4. Data Triangulation and Validation
28. PREFILLED SYRINGES MARKET, BY TYPE OF BARREL MATERIAL
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Prefilled Syringes Market: Distribution by Type of Barrel Material, 2018, 2023 and 2035
28.3.1. Glass Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.2. Plastic Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.4. Data Triangulation and Validation
29. PREFILLED SYRINGES MARKET, BY NUMBER OF CHAMBER
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Prefilled Syringes Market: Distribution by Number of Chamber, 2018, 2023 and 2035
29.3.1. Single Chamber Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.3.2. Dual Chamber Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.4. Data Triangulation and Validation
30. PREFILLED SYRINGES MARKET, BY TYPE OF NEEDLE SYSTEM
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Prefilled Syringes Market: Distribution by Type of Needle System, 2018, 2023 and 2035
30.3.1. Staked Needle Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2. Luer Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.4. Data Triangulation and Validation
31. PREFILLED SYRINGES MARKET, BY USABILITY OF SYRINGE
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Prefilled Syringes Market: Distribution by Usability of Syringe, 2018, 2023 and 2035
31.3.1. Disposable Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
31.3.2. Reusable Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
31.4. Data Triangulation and Validation
32. PREFILLED SYRINGES MARKET, BY TYPE OF SYRINGE
32.1. Chapter Overview
32.2. Key Assumptions and Methodology
32.3. Prefilled Syringes Market: Distribution by Type of Syringe, 2018, 2023 and 2035
32.3.1. Conventional Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
32.3.1. Safety Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
32.4. Data Triangulation and Validation
33. PREFILLED SYRINGES MARKET, BY TYPE OF PACKAGING
33.1. Chapter Overview
33.2. Key Assumptions and Methodology
33.3. Prefilled Syringes Market: Distribution by Type of Packaging, 2018, 2023 and 2035
33.3.1. Bulk Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
33.3.2. Nested Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
33.4. Data Triangulation and Validation
34. PREFILLED SYRINGES MARKET, BY KEY GEOGRAPHICAL REGIONS
34.1. Chapter Overview
34.2. Key Assumptions and Methodology
34.3. Prefilled Syringes Market: Distribution by Key Geographical Region, 2018, 2023 a
1.1. Prefilled Syringes Market
1.2. Market Share Insights
1.2.1 Market Segmentation Overview
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. History of Prefilled Syringes
5.3. Benefits of Prefilled Syringes Over Traditional Injectable Devices
5.3.1. Benefits of Prefilled Syringes for Healthcare Professionals and End Users
5.3.2. Benefits of Prefilled Syringes for Manufacturers
5.3.3. Transition from Existing Dosing Forms to Prefilled Syringes
5.4. Prefilled Syringe Components
5.5. Classification of Prefilled Syringes
5.5.1. Classification based on Barrel Fabrication Material
5.5.1.1. Glass Barrel Prefilled Syringes
5.5.1.1.1. Limitations of Glass Barrel Prefilled Syringes
5.5.1.1.2. Addressing the Limitations of Glass Barrel Prefilled Syringes
5.5.1.2. Plastic Barrel Prefilled Syringes
5.5.1.2.1. Limitations of Plastic Barrel Prefilled Syringes
5.5.1.2.2. Addressing the Limitations of Plastic Barrel Prefilled Syringes
5.5.1.2.3. Factors Likely to Drive the Use of Plastic Prefilled Syringes
5.5.2. Classification based on Number of Chambers in the Barrel
5.5.3. Classification based on Type of Needle
5.5.4. Classification based on Type of Packaging
5.6. Critical Attributes of Prefilled Syringe Design
5.7. Key Manufacturing Steps for Prefilled Syringes
5.7.1. Production of Barrels
5.7.1.1. Glass Barrels
5.7.1.2. Plastic Barrels
5.7.2. Production of Syringes
5.7.3. Barrel Siliconization
5.7.4. Syringe Sterilization
5.7.5. Validation of Sterilization
5.7.6. Syringe Filling
5.7.7. Syringe Testing
5.8. Future Perspectives
6. PREFILLED SYRINGES: MARKET OVERVIEW
6.1. Chapter Overview
6.2. Prefilled Syringes: Overall Market Landscape
6.2.1. Analysis by Type of Barrel Fabrication Material
6.2.2. Analysis by Number of Barrel Chambers
6.2.3. Analysis by Type of Needle System
6.2.4. Analysis by Volume of Syringe
6.3. Prefilled Syringes Manufacturers: Overall Market Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Analysis by Company Size and Location of Headquarters
6.3.5. Analysis by Location of Manufacturing Facilities
6.3.6. Most Active Players: Analysis by Number of Prefilled Syringes
7. PRODUCT COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Product Competitiveness Analysis: Prefilled Syringes
7.4.1. Glass Barrel Prefilled Syringes
7.4.2. Plastic Barrel Prefilled Syringes
8. COMPANY PROFILES: PREFILLED SYRINGE MANUFACTURERS IN NORTH AMERICA
8.1. Chapter Overview
8.2. Detailed Company Profiles of Leading Prefilled Syringe Manufacturers
8.3.1 Becton, Dickinson and Company
8.3.1.1. Company Overview
8.3.1.2. Financial Information
8.3.1.3. Becton, Dickinson and Company Prefilled Syringes Portfolio
8.3.1.4. Recent Developments and Future Outlook
8.3.2. Medefil
8.3.2.1. Company Overview
8.3.2.2. Medefil Prefilled Syringes Portfolio
8.3.2.3. Recent Developments and Future Outlook
8.3.3. West Pharmaceutical
8.3.3.1. Company Overview
8.3.3.2. Financial Information
8.3.3.2. West Pharmaceutical Prefilled Syringes Portfolio
8.3.3.3. Recent Developments and Future Outlook
8.4. Short Profiles of Other Prominent Prefilled Syringe Manufacturers
8.4.1. Medline
8.4.1.1. Company Overview
8.4.1.2. Prefilled Syringes Portfolio
8.4.2. MedXL
8.4.2.1. Company Overview
8.4.2.2. Prefilled Syringes Portfolio
8.4.3 Pfizer
8.4.3.1. Company Overview
8.4.3.2. Prefilled Syringes Portfolio
9. COMPANY PROFILES: PREFILLED SYRINGE MANUFACTURERS IN EUROPE
9.1. Chapter Overview
9.2. Detailed Company Profiles of Leading Prefilled Syringe Manufacturers
9.3.1. Gerresheimer
9.3.1.1. Company Overview
9.3.1.2. Financial Information
9.3.1.3. Gerresheimer Prefilled Syringes Portfolio
9.3.1.4. Recent Developments and Future Outlook
9.3.2 SCHOTT
9.3.2.1. Company Overview
9.3.2.2. Financial Information
9.3.2.3. Schott Prefilled Syringes Portfolio
9.3.2.4. Recent Developments and Future Outlook
9.3.3. Stevanato
9.3.3.1. Company Overview
9.3.2.2. Financial Information
9.3.3.3. Stevanato Prefilled Syringes Portfolio
9.3.3.4. Recent Developments and Future Outlook
9.4. Short Profiles of Other Prominent Prefilled Syringe Manufacturers
9.4.1 B. Braun
9.4.1.1. Company Overview
9.4.1.2. Prefilled Syringes Portfolio
9.4.2. Nipro Europe
9.4.2.1. Company Overview
9.4.2.2. Prefilled Syringes Portfolio
9.4.3. Vetter Pharma
9.4.3.1. Company Overview
9.4.3.2. Prefilled Syringes Portfolio
10. COMPANY PROFILES: PREFILLED SYRINGE MANUFACTURERS IN ASIA-PACIFIC
10.1. Chapter Overview
10.2. Detailed Company Profiles of Leading Prefilled Syringe Manufacturers
10.2.1 Shandong Zibo Minkang Pharmaceutical Packing
10.2.1.1. Company Overview
10.2.1.2. Shandong Zibo Minkang Pharmaceutical Packing Prefilled Syringes Portfolio
10.2.1.3. Recent Developments and Future Outlook
10.2.2. Shin Yan Sheno Precision Industrial
10.2.2.1. Company Overview
10.2.2.2. Taisei Kako Prefilled Syringes Portfolio
10.2.2.3. Recent Developments and Future Outlook
10.2.3. Taisei Kako
10.2.3.1. Company Overview
10.2.3.2. Taisei Kako Prefilled Syringes Portfolio
10.2.3.3. Recent Developments and Future Outlook
10.3. Short Profiles of Other Prominent Prefilled Syringe Manufacturers
10.3.1 J.O.Pharma
10.3.1.1. Company Overview
10.3.1.2. Prefilled Syringes Portfolio
10.3.2. Shandong Pharmaceutical Glass
10.3.2.1. Company Overview
10.3.2.2. Prefilled Syringes Portfolio
10.3.3. Shandong Weigao Group Medical Polymer
10.3.3.1. Company Overview
10.3.3.2. Prefilled Syringes Portfolio
11. NEEDLESTICK INJURIES
11.1. Chapter Overview
11.2. Incidence and Associated Financial Burden
11.3. Government Legislations for Prevention of Needlestick Injuries
11.4. Safety Mechanisms used in Modern Prefilled Syringes
11.4.1. Safety Systems: Add-On Safety Device Manufacturers
11.4.1.1. Becton Dickinson and Company
11.4.1.2. Nemera
11.4.1.3. Nipro PharmaPackagin
11.4.1.4. Terumo
11.4.1.5. West Pharmaceutical
11.4.2. Safety Systems: Integrated Safety Device Manufacturers
11.4.2.1. Gerresheimer
11.4.2.2. Injecto
11.4.2.3. MedicalChain International
11.4.2.4. Stevanato
11.4.2.5. Owen Mumford
11.4.2.6. SHL Group
11.4.2.7. Taisei Kako
12. REGULATORY LANDSCAPE FOR PREFILLED SYRINGES
12.1. Chapter Overview
12.2. Regulatory Approval of Combination Products in North America
12.2.1. Regulatory Approval of Combination Products in the US
12.2.1.1. Overview
12.2.1.2. Historical Background
12.1.1.3. Role of Regulatory Bodies in Product Approval
12.1.1.4. Regulatory Approval of Prefilled Syringes
12.1.1.4.1. Reimbursement Landscape in the US
12.1.1.4.2. Payer Mix
12.1.1.4.3.. Reimbursement Process in the US
12.2.2. Regulatory Approval of Combination Products in Canada
12.2.2.1. Overview
12.2.2.2. Role of Regulatory Bodies in Product Approval
12.2.2.3. Regulatory Approval for Prefilled Syringes
12.2.2.3.1. Reimbursement Landscape in Canada
12.2.2.3.2. Payer Mix
12.2.2.3.3. Reimbursement Process in Canada
12.3. Regulatory Approval of Combination Products in Europe
12.3.1. Overview
12.3.2. Role of Regulatory Bodies in Product Approval
12.3.3. Regulatory Approval of Prefilled Syringes
12.3.4. Regulatory Approval of Combination Products in the UK
12.3.4.1. Reimbursement Landscape in the UK
12.3.4.2. Payer Mix
12.3.4.3. Reimbursement Process in the UK
12.3.5. Regulatory Approval of Combination Products in France
12.3.5.1. Reimbursement Landscape in France
12.3.5.2. Payer Mix
12.3.5.3. Reimbursement Process in France
12.3.6. Regulatory Approval of Combination Products in Spain
12.3.6.1. Reimbursement Landscape in Spain
12.3.6.2. Payer Mix
12.3.6.3. Reimbursement Process in Spain
12.3.7. Regulatory Approval of Combination Products in Spain
12.3.7.1. Reimbursement Landscape in Germany
12.3.7.2. Payer Mix
12.3.7.3. Reimbursement Process in Germany
12.3.8. Regulatory Approval of Combination Products in Italy
12.3.8.1. Reimbursement Landscape in Italy
12.3.8.2. Payer Mix
12.3.8.3. Reimbursement Process in Italy
12.4. Regulatory Approval of Combination Products in Asia-Pacific
12.4.1. Regulatory Approval of Combination Products in Japan
12.4.1.1 Overview
12.4.1.2 Role of Regulatory Bodies in Product Approval
12.4.1.3. Regulatory Approval of Prefilled Syringes
12.4.1.3.1. Reimbursement Landscape in Japan
12.4.1.3.2. Payer Mix
12.4.1.3.3. Reimbursement Process in Japan
12.4.2. Regulatory Approval of Combination Products in China
12.4.2.1. Overview
12.4.2.2. Role of Regulatory Bodies in Product Approval
12.4.2.3. Regulatory Approval for Prefilled syringes
12.4.2.3.1. Reimbursement Landscape in China
12.4.2.3.2. Payer Mix
12.4.2.3.3. Reimbursement Process in China
12.4.3. Regulatory Approval of Combination Products in India
12.4.3.1. Overview
12.4.3.2. Role of Regulatory Bodies in Product Approval
12.4.3.3. Regulatory Approval of Prefilled Syringes
12.4.3.3.1. Reimbursement Landscape in India
12.4.3.3.2. Payer Mix
12.4.4. Regulatory Approval of Combination Products in South Korea
12.4.4.1. Overview
12.4.4.2. Role of Regulatory Bodies in Product Approval
12.4.4.3. Regulatory Approval of Prefilled Syringes
12.4.4.3.1. Reimbursement Landscape in South Korea
12.4.4.3.2. Payer Mix
12.4.4.3.3. Reimbursement Process in South Korea
12.4.5. Regulatory Approval of Combination Products in Saudi Arabia
12.4.5.1. Overview
12.4.5.2. Role of Regulatory Bodies in Product Approval
12.4.5.3. Regulatory Approval of Prefilled syringes
12.4.5.3.1. Reimbursement Landscape in Saudi Arabia
12.4.5.3.2. Payer Mix
12.4.5.3.3. Reimbursement Process in Saudi Arabia
12.4.6. Regulatory Approval of Combination Products in United Arab Emirates
12.4.6.1. Overview
12.4.6.2. Role of Regulatory Bodies in Product Approval
12.4.6.3. Regulatory Approval of Prefilled syringes
12.4.6.3.1. Reimbursement Landscape in United Arab Emirates
12.4.6.3.2. Payer Mix
12.4.6.3.3. Reimbursement Process in United Arab Emirates
12.5. Regulatory Approval of Combination Products in Rest of the World
12.5.1. Regulatory Approval of Combination Products in Brazil
12.5.1.1 Overview
12.5.1.2 Role of Regulatory Bodies in Product Approval
12.5.1.3. Regulatory Approval of Prefilled Syringes
12.5.1.3.1. Reimbursement Landscape in Brazil
12.5.1.3.2. Payer Mix
12.5.1.3.3. Reimbursement Process in Brazil
12.5.2. Regulatory Approval of Combination Products in Australia
12.5.2.1 Overview
12.5.2.2 Role of Regulatory Bodies in Product Approval
12.5.2.3. Regulatory Approval of Prefilled Syringes
12.5.2.3.1. Reimbursement Landscape in Australia
12.5.2.3.2. Payer Mix
12.5.2.3.3. Reimbursement Process in Australia
13. PREFILLED SYRINGE COMBINATION PRODUCTS
13.1. Chapter Overview
13.2. Prefilled Syringe Combination Products: Approved Drugs
13.2.1. Analysis by Type of Drug Molecule
13.2.2. Analysis by Product Approval
13.2.3. Analysis by Route of Administration
13.2.4. Analysis by Target Therapeutic Area
13.2.5. Analysis by Region of Product Analysis
13.2.6. Analysis by Other Approved Primary Packaging Systems
13.3. Prefilled Syringe Combination Products: Clinical Stage Drugs
13.3.1. Analysis by Type of Drug Molecule
13.3.2. Analysis by Phase of Development
13.3.3. Analysis by Route of Administration
13.3.4. Analysis by Target Therapeutic Area
13.4. Prefilled Syringe Combination Products: Developers Landscape
13.4.1. Analysis by Year of Establishment
13.4.2. Analysis by Company Size
13.4.3. Analysis by Location of Headquarters
13.5. Leading Drugs in Prefilled Syringe Format
13.6. Other Drugs Available in Prefilled Syringe Format
13.7. Most Popular Drug Available in Prefilled Syringe Format: Humira (adalimumab), AbbVie / Eisai
13.7.1. Target Indications and Available Dosage Forms
13.7.2. Shift from Vials to Prefilled Syringes
13.7.3. Humira Annual Sales, FY 2010-FY 2022
14. KEY THERAPEUTIC AREAS
14.1. Chapter Overview
14.2. Autoimmune Disorders
14.2.1. Approved Drugs
14.2.2. Key Developments
14.2.3. Upcoming / Commercialized Biosimilars for Autoimmune Drugs
14.3. Infectious Diseases
14.3.1. Approved Drugs
14.3.2. Key Developments
14.4. Neurological Disorders
14.4.1. Approved Drugs
14.4.2. Key Developments
15. PREFILLED SYRINGES: LIKELY DRUG CANDIDATES ANALYSIS
15.1. Chapter Overview
15.2. Likely Drug Candidates
15.2.1. Assumption and Key Parameters
15.2.2. Methodology
15.2.3. Most Likely Candidates for Delivery via Prefilled Syringes
15.2.4. Likely Candidates for Delivery via Prefilled Syringes
15.2.5. Less Likely Candidates for Delivery Via Prefilled Syringe
16. COMBINATION PRODUCTS: BIG PHARMA ACTIVITY
16.1. Chapter Overview
16.2. Methodology
16.3. Combination Products: Big Pharma Activity
16.3.1. Analysis by Target Therapeutic Area
16.3.1.1. Autoimmune Disorders
16.3.1.2. Infectious Diseases
16.3.1.3. Neurological Disorders
16.3.1.4. Blood Disorders
16.3.1.5. Oncological Disorders
16.3.2. Analysis by Type of Molecule
16.3.2.1. Antibodies
16.3.2.2. Vaccines
16.3.2.3. Proteins
16.3.2.4. Peptides
16.3.2.5. Small Molecules
16.3.2.6. Other Biologics
17. RECENT DEVELOPMENTS
17.1. Chapter Overview
17.2. Prefilled Syringes: Recent Developments
17.3. Analysis by Year of Initiative
17.4. Analysis by Type of Initiative
17.5. Analysis by Year and Type of Initiative
17.5.1. Analysis by Location of Expansion
17.5.2. Analysis by Type of Expansion
17.5.3 Analysis by Type of Partnership
17.6. Analysis by Geography
17.7. Most Active Players: Distribution by Number of Recent Initiatives
17.8. Analysis of Player by Type of Initiatives
18. PATENT ANALYSIS
18.1. Chapter Overview
18.2. Scope and Methodology
18.3. Prefilled Syringes: Patent Analysis
18.3.1. Analysis by Patent Publication Year
18.3.2. Analysis by Type of Patent and Publication Year
18.3.3. Analysis by Patent Application Year
18.3.4. Analysis by Patent Jurisdiction
18.3.5. Analysis by CPC Symbols
18.3.6. Analysis by Type of Applicant
18.3.7. Leading Players: Analysis by Number of Patents
18.3.8. Leading Individual Assignees: Analysis by Number of Patents
18.4. Prefilled Syringes: Patent Benchmarking Analysis
18.4.1. Analysis by Patent Characteristics
18.5. Prefilled Syringes: Patent Valuation Analysis
18.6. Leading Patents by Number of Citations
19. KOL ANALYSIS
19.1. Chapter Overview
19.2. Assumption and Key Parameters
19.3. Methodology
19.4. Prefilled Syringes: Key Opinion Leaders
19.4.1. Analysis by Role of KOL
19.4.2. Analysis by Type of Sponsor Organization
19.4.3. Analysis by Affiliated Organization
19.4.4. Analysis by Target Disease Indication
19.4.5. Analysis by Geographical Location
19.4.6. Most Prominent KOLs: Analysis by Activeness, Expertise and Strength of KOL
19.4.7. Most Prominent KOLs: Analysis by RA score
20. SPECIALTY PREFILLED SYRINGES
20.1. Chapter Overview
20.2. Prefilled Flush Syringes
20.2.1. Overview
20.2.2. Advantages of Prefilled Flush Syringes
20.2.3. Prefilled Flush Syringes Available in the Market
20.3. Prefilled Diluent Syringes
20.3.1. Overview
20.3.2. Advantages of Prefilled Diluent Syringes
20.3.3. Lyophilized Drugs Available in Prefilled Diluent Syringes
20.4. Contrast Agent Prefilled Syringes
20.4.1. Overview
20.4.2. Advantages of Using Prefilled Syringes for Contrast Agents
20.4.3. Contrast Agents Available in Prefilled Syringes
21. TECHNOLOGICAL ADVANCES RELATED TO PREFILLED SYRINGES
21.1. Chapter Overview
21.2. Prefilled Syringes for Lyophilized Drugs
21.2.1. Prefilled Diluent Syringes
21.2.2. Prefilled Dual-Chamber Syringes
21.3. Multilayer Plastic Prefilled Syringes with Oxygen Barrier
21.4. Prefilled Syringes with Low Risk of Particle Formation
21.5. Advanced Lubrication Technology for Prefilled Syringes
21.6. Advances in Terminal Sterilization of Prefilled Syringes
21.7. Prefilled Syringe Usage Aids for Patients and Healthcare Providers
21.8. Additional Advancements
22. KEY GROWTH DRIVERS
22.1. Chapter Overview
22.2. Rising Incidence of Chronic Diseases
22.3. Growing Preference for Self-Injection
22.4. Evolving Patient Demographics
22.5. Growth of Biologics and Biosimilars Market
22.6. Changing Pharmaceutical Practices
22.7. Increasing Focus on Prevention of Needlestick Injuries
22.8. Prefilled Syringes in Autoinjectors and Pen Injectors
23. SWOT ANALYSIS
23.1. Chapter Overview
23.2. Strengths
23.2.1. Ease of Use
23.2.2. Ability to Reduce / Eliminate Medication Errors
23.2.3. Reducing the Risk of Accidental Transmission of Blood-Borne Pathogens
23.2.4. Economic Advantages
23.2.5. Drug Life Cycle Management
23.3. Weaknesses
23.3.1. Manufacturing Complexities
23.3.2. High Packaging and Transportation Costs
23.3.3. Product Stability and Quality Related Issues
23.3.4. Challenges Associated with Drug Filing
23.4. Opportunities
23.4.1. Rich and Growing Pipeline of Biologics and Biosimilars
23.4.2. Growing Preference for Self-Injecting
23.4.3. Application in Advanced Drug Delivery Devices
23.4.4. Innovation in Design and Technical Advancement
23.4.5. Rising Popularity across the Globe
23.4.6. Widespread Use in Vaccination Programs
23.5. Threats
23.5.1. Material Compatibility Issues
23.5.2. Availability of Alternative Drug Delivery Devices
23.5.3. Concern Related to Numerous Product Recalls In Past
23.6. Concluding Remarks
24. GLOBAL PREFILLED SYRINGES MARKET
24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Global Prefilled Syringes Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.1. Scenario Analysis
24.4. Key Market Segmentations
25. PREFILLED SYRINGES MARKET, BY PURPOSE OF SYRINGE
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Prefilled Syringes Market: Distribution by Purpose of Syringe, 2018, 2023 and 2035
25.3.1. Specialty Prefilled Syringe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.2. Therapeutic Prefilled Syringe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.3. Cosmetic Prefilled Syringe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.4. Data Triangulation and Validation
26. PREFILLED SYRINGES MARKET, BY TYPE OF MOLECULE
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Prefilled Syringes Market: Distribution by Type of Molecule, 2018, 2023 and 2035
26.3.1. Prefilled Syringes Market for Proteins: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.2. Prefilled Syringes Market for Antibodies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.3. Prefilled Syringes Market for Peptides: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.4. Prefilled Syringes Market for Small Molecules: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.5. Prefilled Syringes Market for Vaccines: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.6. Prefilled Syringes Market for Cell Therapies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.4. Data Triangulation and Validation
27. PREFILLED SYRINGES MARKET, BY THERAPEUTIC AREA
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Prefilled Syringes Market: Distribution by Therapeutic Area, 2018, 2023 and 2035
27.3.1. Prefilled Syringes Market for Blood Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.2. Prefilled Syringes Market for Infectious Diseases: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.3. Prefilled Syringes Market for Autoimmune Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.4. Prefilled Syringes Market for Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.5. Prefilled Syringes Market for Cardiovascular Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.6. Prefilled Syringes Market for Respiratory Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.7. Prefilled Syringes Market for Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.8. Prefilled Syringes Market for Metabolic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.9. Prefilled Syringes Market for Ophthalmic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.10. Prefilled Syringes Market for Orthopedic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.11 Prefilled Syringes Market for Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.4. Data Triangulation and Validation
28. PREFILLED SYRINGES MARKET, BY TYPE OF BARREL MATERIAL
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Prefilled Syringes Market: Distribution by Type of Barrel Material, 2018, 2023 and 2035
28.3.1. Glass Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.2. Plastic Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.4. Data Triangulation and Validation
29. PREFILLED SYRINGES MARKET, BY NUMBER OF CHAMBER
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Prefilled Syringes Market: Distribution by Number of Chamber, 2018, 2023 and 2035
29.3.1. Single Chamber Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.3.2. Dual Chamber Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.4. Data Triangulation and Validation
30. PREFILLED SYRINGES MARKET, BY TYPE OF NEEDLE SYSTEM
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Prefilled Syringes Market: Distribution by Type of Needle System, 2018, 2023 and 2035
30.3.1. Staked Needle Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2. Luer Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.4. Data Triangulation and Validation
31. PREFILLED SYRINGES MARKET, BY USABILITY OF SYRINGE
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Prefilled Syringes Market: Distribution by Usability of Syringe, 2018, 2023 and 2035
31.3.1. Disposable Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
31.3.2. Reusable Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
31.4. Data Triangulation and Validation
32. PREFILLED SYRINGES MARKET, BY TYPE OF SYRINGE
32.1. Chapter Overview
32.2. Key Assumptions and Methodology
32.3. Prefilled Syringes Market: Distribution by Type of Syringe, 2018, 2023 and 2035
32.3.1. Conventional Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
32.3.1. Safety Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
32.4. Data Triangulation and Validation
33. PREFILLED SYRINGES MARKET, BY TYPE OF PACKAGING
33.1. Chapter Overview
33.2. Key Assumptions and Methodology
33.3. Prefilled Syringes Market: Distribution by Type of Packaging, 2018, 2023 and 2035
33.3.1. Bulk Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
33.3.2. Nested Prefilled Syringes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
33.4. Data Triangulation and Validation
34. PREFILLED SYRINGES MARKET, BY KEY GEOGRAPHICAL REGIONS
34.1. Chapter Overview
34.2. Key Assumptions and Methodology
34.3. Prefilled Syringes Market: Distribution by Key Geographical Region, 2018, 2023 a